Gracell Biotechnologies Inc. (GRCL) — Net Asset Quality Index
Gracell Biotechnologies Inc. (GRCL) has a Net Asset Quality Index of 85.8% as of September 2023. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $1.89 Billion minus total liabilities of $268.86 Million yields net assets of $1.62 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check GRCL asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Gracell Biotechnologies Inc. Net Asset Quality Index Over Time (2018–2022)
This chart shows how Gracell Biotechnologies Inc.'s Net Asset Quality Index has evolved across 5 annual periods from 2018 to 2022. As of September 2023, the index stands at 85.8%, representing net assets of $1.62 Billion against total assets of $1.89 Billion USD. See Gracell Biotechnologies Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Gracell Biotechnologies Inc. (2018–2022)
The table below presents the year-by-year Net Asset Quality Index for Gracell Biotechnologies Inc. from 2018 to 2022, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see GRCL market cap.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 83.1% | $1.38 Billion | $1.66 Billion | $280.51 Million | ▼ -5.6 pp |
| 2021 | 88.7% | $1.83 Billion | $2.06 Billion | $232.77 Million | ▲ +3.8 pp |
| 2020 | 84.9% | $819.66 Million | $964.95 Million | $145.29 Million | ▲ +23.0 pp |
| 2019 | 61.9% | $255.36 Million | $412.22 Million | $156.86 Million | ▲ +60.3 pp |
| 2018 | 1.6% | $2.38 Million | $148.52 Million | $146.13 Million | — |